Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk

References

• Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation119, e21–e181 (2009).
   PubMed Web of Science ®Google Scholar
• Kannel WB, Dawber TR, Friedman GD, Glennon WE, McNamara PM. Risk factors in coronary heart disease. an evaluation of several serum lipids as predictors of coronary heart disease; the Framingham study. Ann. Intern. Med.61, 888–899 (1964).
   PubMed Web of Science ®Google Scholar
• Anitschkow N and Chalatow S; translated by Pelias MZ. On experimental cholesterin steatosis and its significance in the origin of some pathological processes. Arterioscler. Thromb. Vasc. Biol.3, 178–182 (1983).
   Google Scholar
• Kannel WB, Dawber TR, Friedman GD et al. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease: the Framingham Study. Ann. Intern. Med.61, 888–899 (1964).
   PubMed Web of Science ®Google Scholar
• Buja LM, Kita T, Goldstein JL et al. Cellular pathology of progressive atherosclerosis in the WHHL rabbit. An animal model of familial hypercholesterolemia. Arteriosclerosis3, 87–101 (1983).
   PubMedGoogle Scholar
• Kruth HS. Lipoprotein cholesterol and atherosclerosis. Curr. Mol. Med.1, 633–653 (2001).
   PubMedGoogle Scholar
• No authors listed. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344, 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Shepherd J. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am. J. Cardiol.76, 113C–117C (1995).
   Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al.; Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med.335, 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• No authors listed. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med.339, 1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA279, 1615–1622 (1998).
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366, 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA294, 2437–2445 (2005).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med.352, 1425–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA295, 1556–1565 (2006).
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet376, 1670–1681 (2010).
   PubMed Web of Science ®Google Scholar
• Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. JACC57, 1666–1675 (2011).
   Google Scholar
• Holdgate GA, Ward WH, McTaggart F. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem. Soc. Trans.31, 528–531 (2003).
   PubMed Web of Science ®Google Scholar
• Kapur NK. Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert Rev. Cardiovasc. Ther.5, 161–175 (2007).
   PubMedGoogle Scholar
• Istvan ES and Deisenhofer J. Structual mechanism for statin inhibition of HMG-CoA reductase. Science292, 1160–1164 (2001).
   PubMed Web of Science ®Google Scholar
• Crestor ® rosuvastatin, product information. AstraZeneca Pharmaceuticals LP, WIlmington, DE, USA (2010).
   Google Scholar
• McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler. (Suppl. 4), 9–14 (2003).
   Google Scholar
• Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug–drug interactions in the clinical setting of dyslipidemia. Am. J. Cardiovasc. Drugs10, 11–28 (2010).
   PubMed Web of Science ®Google Scholar
• Nezasa K, Higaki K, Takeuchi M, Nakano M, Koike M. Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica33, 379–388 (2003).
   PubMed Web of Science ®Google Scholar
• Mach F, Sennouf D, Fontana P et al. Not all statins interfere with clopidogrel during antiplatelet therapy. Eur. J. Clin. Invest.35, 476–481 (2005).
   PubMed Web of Science ®Google Scholar
• Riondino S, Petrini N, Donato L et al. Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. J. Thromb. Thrombolysis28, 151–155 (2009).
   PubMedGoogle Scholar
• McKenney JM. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am. J. Cardiol.96, 60E–66E (2005).
   PubMed Web of Science ®Google Scholar
• Schaefer JR, Schweer H, Ikewaki K et al. Metabolic basis of high density lipoproteins and apolipoprotein A-1 increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis144, 177–184 (1999).
   PubMed Web of Science ®Google Scholar
• Martin G, Duez H, Blanquart C et al. Statin-induced inhibition of the RHO-signaling pathway activates PPARalpha and induces HDL apoA-1. J. Clin. Invest.107, 1423–1432 (2001).
   PubMed Web of Science ®Google Scholar
• Toth PP. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am. J. Cardiol.96, 50K–58K (2005).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med.359, 2195–2207 (2008).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Genest J, Boekholdt SM et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet376, 333–339 (2010).
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol.92, 152–160 (2003).
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am. J. Cardiol.105, 69–76 (2010).
   PubMed Web of Science ®Google Scholar
• Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J. Lipid Res.51, 1546–1553 (2010).
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur. J. Pharmacol.590, 327–332 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care32, 1087–1091 (2009).
   Web of Science ®Google Scholar
• Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation96, 1432–1437 (1997).
   PubMed Web of Science ®Google Scholar
• Chambless LE, Heiss G, Folsom AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am. J. Epidemiol.146, 483–494 (1997).
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, LaBree L et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med.128, 262–269 (1998).
   PubMed Web of Science ®Google Scholar
• O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N. Engl. J. Med.340, 14–22 (1999).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke35, 2902–2909 (2004).
   PubMed Web of Science ®Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet357, 577–581 (2001).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation106, 2055–2060 (2002).
   PubMed Web of Science ®Google Scholar
• Crouse JR 3rd, Raichlen JS, Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA297, 1344–1353 (2007).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA291, 1071–1080 (2004).
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Sipahi I et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am. J. Cardiol.97, 1553–1557 (2006).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Raichlen JS, Nicholls SJ et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation117, 2458–2466 (2008).
   PubMed Web of Science ®Google Scholar
• Takayama T, Hiro T, Yamagishi M et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ. J.73, 2110–2117 (2009).
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Sipahi I et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA297, 499–508 (2007).
   PubMed Web of Science ®Google Scholar
• Fayad ZA, Nahar T, Fallon JT et al.In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography. Circulation101, 2503–2509 (2000).
   PubMed Web of Science ®Google Scholar
• Corti R, Fayad ZA, Fuster V et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation104, 249–252 (2001).
   PubMed Web of Science ®Google Scholar
• Corti R, Fuster V, Fayad ZA et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years’ follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation106, 2884–2887 (2002).
   PubMed Web of Science ®Google Scholar
• Underhill HR, Yuan C, Zhao XQ et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am. Heart J.155, 584.e1–e8 (2008).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet373, 1175–1182 (2009).
   PubMed Web of Science ®Google Scholar
• de Lorgeril M, Salen P, Abramson J et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin–JUPITER controversy. A critical reappraisal. Arch. Intern. Med.170, 1032–1036 (2010).
   PubMed Web of Science ®Google Scholar
• Kaul S, Morrissey RP, Diamond GA. By Jove! What is a clinician to make of JUPITER? Arch. Intern. Med.201, 170, 1073–1077 (2010).
   Google Scholar
• Green LA. Cholesterol-lowering therapy for primary prevention, still much we don’t know. Arch. Intern. Med.170, 1007–1008 (2010).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Glynn RJ. The JUPITER trial: responding to the critics. Am. J. Cardiol.106, 1351–1356 (2010).
   PubMed Web of Science ®Google Scholar
• Glynn RJ, Danielson E, Fonseca FA et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med.360, 1851–1861 (2009).
   PubMed Web of Science ®Google Scholar
• GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet372, 1231–1239 (2008).
   PubMed Web of Science ®Google Scholar
• Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med.357, 2248–2261 (2007).
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Kjekshus J, Gullestad L et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation120, 2188–2196 (2009).
   PubMed Web of Science ®Google Scholar
• Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med.360, 1395–1407 (2009).
   PubMed Web of Science ®Google Scholar
• Wanner C, Krane V, Marz W et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med.353, 238–248 (2005).
   PubMed Web of Science ®Google Scholar
• Sharp Collaborative G. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am. Heart J.160, 785–794.e10 (2010).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Hunninghake DB, Stein EA et al. Safety of rosuvastatin. Am. J. Cardiol.94, 882–888 (2004).
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet375, 735–742 (2010).
   PubMed Web of Science ®Google Scholar
• Lee KK, Cipriano LE, Owens DK et al. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate – and low-cardiovascular-risk individuals for statin therapy. Circulation122, 1478–1487 (2010).
   Google Scholar
• Choudhry NK, Patrick AR, Glynn RJ. The cost–effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. JACC57, 784–791 (2011).
   Google Scholar
• Goldstein LB, Bushnell CD, Adams RJ et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke42, 517–584 (2011).
   PubMed Web of Science ®Google Scholar